Drug-induced cutaneous lupus erythematosus after immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a case series

Journal of the Peripheral Nervous System

Volumn 22, Issue 3, 2017, Pages 213-218

  Adrichem, Max E ^a   Starink, Markus V ^a   van Leeuwen, Ester M M ^a   Kramer, Christine ^b   van Schaik, Ivo N ^a   Eftimov, Filip ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Sanquin Plasmaproducten   (Netherlands)

Author keywords

adverse effects; CIDP; cutaneous lupus erythematosus; IgG treatment

Indexed keywords

CORTICOSTEROID DERIVATIVE; IMMUNOGLOBULIN; RO ANTIBODY; RO52 ANTIBODY; RO60 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CASE REPORT; CASE STUDY; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RELAPSE; REMISSION; SKIN BIOPSY; SKIN LUPUS ERYTHEMATOSUS; CHEMICALLY INDUCED; PATHOLOGY; PATHOPHYSIOLOGY; POLYRADICULONEUROPATHY;

ADULT; AGED; FEMALE; HUMANS; IMMUNOGLOBULINS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; MIDDLE AGED; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

EID: 85028919798     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/jns.12218     Document Type: Article

References (20)

1. Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N (2012). Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol 32:1180–1192.
2. Baxter AG (2010). SPC KIOVIG 100 mg/ml Solution for Infusion. Baxalta UK Limited Surrey, UK.
3. Draelos ZD (2008). Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Curr Med Res Opin 24:985–994.
4. Farhi D, Viguier M, Cosnes A, Reygagne P, Dubertret L, Revuz J, Roujeau JC, Bachelez H (2006). Terbinafine-induced subacute cutaneous lupus erythematosus. Dermatology (Basel, Switzerland) 212:59–65.
5. Gerstenblith MR, Antony AK, Junkins-Hopkins JM, Abuav R (2012). Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy. J Am Acad Dermatol 66:312–316.
6. Goodfield M, Davison K, Bowden K (2004). Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat 15:46–50.
7. Goodrich AL, Kohn SR (1993). Hydrochlorothiazide-induced lupus erythematosus: a new variant? J Am Acad Dermatol 28:1001–1002.
8. Grillo JA, Gorson KC, Ropper AH, Lewis J, Weinstein R (2001). Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders. Neurology 57:1699–1701.
9. Gronhagen CM, Fored CM, Linder M, Granath F, Nyberg F (2012). Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case–control study of 234 patients in Sweden. Br J Dermatol 167:296–305.
10. Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Latov N, Merkies IS, van Doorn PA (2008). Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7:136–144.
11. Lee LA, Roberts CM, Frank MB, McCubbin VR, Reichlin M (1994). The autoantibody response to Ro/SSA in cutaneous lupus erythematosus. Arch Dermatol 130:1262–1268.
12. Lowe GC, Henderson CL, Grau RH, Hansen CB, Sontheimer RD (2011). A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol 164:465–472.
13. Marsch AF, Dacso M, High WA, Junkins-Hopkins JM (2015). Histopathologic distinguishing features between lupus and lichenoid keratosis on the face. Am J Dermatopathol 37:875–881; quiz 882–874.
14. van der Molen RG, Hamann D, Jacobs JF, van der Meer A, de Jong J, Kramer C, Strengers PF, van der Meer JW (2015). Anti-SSA antibodies are present in immunoglobulin preparations. Transfusion 55:832–837.
15. O'Shaughnessy DHR, Kane P, Foster M, McManus A (2012). Second National Immunoglobulin Database Report (2010–2011). National Health Service (NHS) (Ed). Manchester.
16. Patel P, Werth V (2002). Cutaneous lupus erythematosus: a review. Dermatol Clin 20:373–385, v.
17. Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA (1985). Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med 103:49–51.
18. Sontheimer RD, Henderson CL, Grau RH (2009). Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res 301:65–70.
19. Stavropoulos PG, Goules AV, Avgerinou G, Katsambas AD (2008). Pathogenesis of subacute cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol 22:1281–1289.
20. Yoshimasu T, Hiroi A, Uede K, Furukawa F (2001). Discoid lupus erythematosus (DLE)-like lesion induced by uracil-tegafur (UFT). Eur J Dermatol 11:54–57.